Gene ther­a­py start­up Lo­can­abio lays off staff, nar­rows fo­cus on Duchenne

Biotech start­up Lo­can­abio has laid off 30% of its work­force, por­tend­ing a lim­it­ed scope go­ing for­ward for the gene ther­a­py de­vel­op­er, backed with more than $150 mil­lion since its 2019 un­veil­ing.

Out of UC San Diego sci­en­tist Gene Yeo and bankrolled by a who’s who of biotech in­vestors, Lo­can­abio’s ini­tial am­bi­tions in­clud­ed var­i­ous neu­rode­gen­er­a­tive, neu­ro­mus­cu­lar and reti­nal dis­eases. The fo­cus now is on Duchenne mus­cu­lar dy­s­tro­phy, specif­i­cal­ly tar­get­ing ex­on 51, CFO Kat Lange told End­points News in an email.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.